New hope for hormone replacement and the heart?**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.  by Petitti, Diana B
EDITORIAL COMMENT
New Hope for Hormone
Replacement and the Heart?*
Diana B. Petitti, MD, MPH
Pasadena, California
In this issue of the Journal, Lindenfeld et al. (1) report an
analysis examining the association between postmenopausal
hormone replacement therapy (HRT) and survival in
women with moderate to severe heart failure (HF). The
data in the analysis are derived from the Beta-Blocker
Evaluation of Survival Trial (BEST), which was a random-
ized trial that compared the effect on survival of a nonse-
lective beta-blocker, bucindolol, with that of placebo in men
and women with moderate to severe HF (2). In the 435
women who were 50 or more years of age, the adjusted
probability of survival 42 months after study entry was 58%
in non-users of HRT and 78% in users. These results are
consistent with those of Reis et al. (3), who examined the
association of postmenopausal HRT with survival in women
with advanced HF based on pooled data from three trials
comparing vesnarinone with placebo. In the Reis et al. (3)
analysis, 12 months after entry, survival was 73% in 897
women who were non-users of HRT and 85% in 237 users
of HRT.
See page 1238
Until five years ago, postmenopausal HRT appeared to
hold great promise in the primary and secondary prevention
of coronary heart disease. Widespread use of postmeno-
pausal hormones for “heart health” was based on data from
observational studies that showed lower incidence and
mortality from coronary disease in users of HRT who were
free of coronary disease and better survival in hormone users
with established coronary disease (4).
The 1998 publication of the results of the Heart and
Estrogen/progestin Replacement study (HERS) (5)—a ran-
domized, placebo-controlled trial of the effect of combined
estrogen/progestin HRT on coronary events in women with
established coronary disease—followed closely by the pub-
lication of the results of the Estrogen Replacement Athero-
sclerosis (ERA) trial (6)—a randomized, placebo-controlled
trial of the effect of combined estrogen/progestin therapy
and estrogen alone on progression of atherosclerosis—
dampened enthusiasm for hormones in prevention of coro-
nary disease. Lack of enthusiasm turned to downright
pessimism with the 2003 publication of further results from
HERS (7) and, more importantly, results of the combined
estrogen/progestin arm of the randomized trial component
of the Women’s Health Initiative (WHI) (8). This arm of
WHI, which involved more than 16,000 women, was
designed to test the effect of hormone replacement in the
primary prevention of coronary heart disease. It unexpect-
edly found a significantly increased risk of coronary heart
disease in women assigned to combined estrogen/progestin
HRT.
In spite of this gloomy picture, hope persists that estrogen
alone—where WHI results are not yet available—or estro-
gen/progestin combinations that were not used in WHI, or
hormones initiated at ages earlier than in WHI might have
a beneficial effect on some aspect of cardiovascular health
(9). The data suggesting that postmenopausal hormone
therapy might affect survival in women with HF are sure to
fuel this hope.
How should this analysis of HF be interpreted in the
context of recent findings from randomized trials of HRT?
Both Lindenfeld et al. (1) and Reis et al. (3) call for a
randomized trial of HRT in women with HF. Is this the
best next step?
The use of data from randomized trials to explore
associations with end points of factors that were not the
subject of the randomization capitalizes on the collection of
data on prognostic factors in HF based on standardized
protocols. Other positive features of well-conducted ran-
domized trials, such as systematic monitoring of the quality
of data collection and careful verification of end points, carry
over to these analyses. Notwithstanding these strengths in
the data from randomized trials, the comparison of hor-
mone users with non-users is vulnerable to uncontrolled,
and even controllable, confounding.
At entry to BEST, users of HRT differed from non-users
in many ways. They were younger, taller, less obese, and
more likely to be white, non-Hispanic. Their HF was more
likely to be nonischemic in origin, and they were less likely
to have history of hypertension and diabetes. Serum creat-
inine, sodium, and ALT, all independent predictors of
mortality in patients with HF, were all significantly lower in
hormone users than in non-users. Statistical adjustment was
used to try to take these differences into account in drawing
conclusions about the effect of hormones on survival.
It has been suggested that “compliance bias” might
explain the lower risk of coronary disease found in obser-
vational studies of hormones and coronary disease (10).
Preventive behaviors differ between hormone users and
non-users (11), leading to the hypothesis that “prevention
bias” might explain the findings of observational studies.
Lindenfeld et al. (1) attempt to eliminate compliance bias
and prevention bias by including measures of health status
and compliance with treatment with study medication in
BEST in a multivariate analysis.
It is doubtful that a measure of health status captures fully
all of the many possible differences in preventive behavior,
health habits, and lifestyle between hormone users and
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non-users. Multivariate analysis does not adjust for what is
poorly measured. With so many measured differences be-
tween the hormone users and non-users in BEST, there are
also likely to be unmeasured differences. Multivariate anal-
ysis does not account for what is not measured. Bias due to
compliance arises not from a specific behavior but from a
panoply of differences that are captured by the decision to be
compliant. It is no surprise that adjustment for compliance
did not alter the relationship between hormone use and
survival. Multivariate analysis does not adjust for what is
unmeasurable. The discrepancy between observational stud-
ies and randomized trials of hormone replacement for
coronary disease should teach us to be not just skeptical, but
extremely skeptical, of the ability of statistical adjustment to
yield valid conclusions about drug efficacy.
Lindenfeld et al. (1) provide an exhaustive review of the
possible mechanisms by which exogenous estrogen or pro-
gestin might have a true biologic effect in decreasing
mortality in women with HF. Absence of a mechanistic
explanation for the observed association would raise serious
questions about whether the observation is real. However,
mechanistic arguments must be viewed cautiously in light of
the randomized trials. The hormone regimens used in the
randomized trials examining coronary heart disease and
measures of coronary atherosclerosis have extensive data to
establish a mechanism for a benefit in preventing coronary
disease and delaying progression of atherosclerosis, includ-
ing favorable effects on total cholesterol, low-density li-
poprotein cholesterol, high-density lipoprotein cholesterol,
fibrinogen, and fasting insulin and glucose (12,13).
Data from both HERS and WHI show that combined
estrogen/progestin HRT at least doubles the risk of venous
thromboembolism (8,14), and several observational studies
show that estrogen alone also increases the risk of venous
thromboembolic disease (15–17). In the WHI, the risk of
ischemic stroke was also increased in users of combined
estrogen/progestin therapy (8). Given the high risk of
venous thromboembolism and stroke in women with HF,
concerns are sure to be raised about the ethics of a trial of
either combined estrogen/progestin therapy or estrogen
alone. Recruitment of women with HF to a trial is likely to
be challenging, even if deemed ethical.
Taken together, the results of the analysis of BEST and
the three vesnarinone trials do not provide much data upon
which to select a regimen of hormone replacement for a
randomized trial. Lindenfeld et al. (1) found no difference in
survival in users of combined estrogen/progestin therapy
compared with estrogen alone. The analysis of data from the
vesnarinone trials found a nonsignificant trend toward less
benefit of combined estrogen/progestin therapy compared
with estrogen alone. The statistical power of the comparison
of estrogen/progestin with estrogen alone was low in both
analyses, and the data are compatible with large differences
in the effect of combined therapy compared with estrogen
alone.
Lindenfeld et al. (1) make much of the fact that the
magnitude of the association between HRT and improved
survival was greater in women whose HF was nonischemic
in origin (hazard ratio 0.35) than in women whose HF was
ischemic (hazard ratio 0.74). The confidence intervals (CIs)
for these estimates of HRT overlap (95% CI 0.14 to 0.87 for
nonischemic HF; 95% CI 0.41 to 1.33 for ischemic HF),
and the claim for a difference between any effect of HRT on
survival in ischemic and nonischemic HF is very tentative.
Importantly, the Reis et al. (3) analysis of data from the
vesnarinone trials did not find any difference in the associ-
ation of HRT with survival between ischemic and nonisch-
emic HF.
The immediate practical importance of having more
clarity on this point is for the design of a randomized trial
that would address the question of a possible effect of HRT
on survival in women with HF. A study that includes HF of
both ischemic and nonischemic etiology would need to be
larger than a study of one or the other type of HF and, thus,
would be more expensive. Given the results of HERS,
recruitment of women with HF with an ischemic etiology to
a trial of hormone replacement would perhaps be more
difficult than recruitment of women with HF without an
ischemic etiology.
A number of relatively recent randomized trials of HF
[e.g., OVERTURE (18), ATLAS (19), CIBIS II (20),
IMPRESS (21)] included reasonably large numbers of
women. Analysis of data from other HF trials with infor-
mation on HRT would be the most important next step to
guide a decision about whether to conduct a randomized
trial of hormone replacement in women with HF. Informa-
tion from such analyses would permit design of the safest
possible trial that would enroll women with the types of HF
that are most likely to benefit from hormone use.
The HF data are a minor reprieve for hormones and the
heart. Knowledge of the past suggests extreme caution, and
clinical practice should not be changed based on these
findings. The path from hormone replacement to cardio-
vascular health is littered with plausible mechanisms, ele-
gant models, consistent data, and anguished analysts.
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